Thymosin Alpha-1
Immune-modulating peptide; Evidence is indication-specific
Brief Overview: Thymosin alpha-1 is an immune-modulating peptide used in some countries as thymalfasin. It is discussed for antiviral, sepsis, vaccine-response, and immune-support contexts. Evidence lens: Evidence is strongest in specific disease settings such as chronic hepatitis B and some sepsis research. It should not be simplified into a universal immune booster. How to read this: if you're new, distinguish immune modulation from immune stimulation. Once you're past the basics, match claims to indication, trial population, immune status, and endpoint.
- A 28-amino-acid acetylated peptide (about 3,108 Da) cleaved from the N-terminus of prothymosin alpha by the enzyme legumain.
- First isolated from calf thymus by Allan Goldstein in 1972 and fully synthesized by 1977.
- The synthetic form, thymalfasin, is sold as Zadaxin by SciClone and is approved in 35+ countries (including China, Italy, and much of Asia) for chronic hepatitis B, chronic hepatitis C, and as an immune adjuvant.
- Not FDA-approved in the United States, though it has held Orphan Drug Designation for hepatocellular carcinoma, chronic hepatitis B, and DiGeorge syndrome.
- Thymosin alpha-1 is an immune-modulating 28-amino-acid peptide used in some countries as thymalfasin/Zadaxin. It is not U.S. FDA-approved.
A bidirectional immune modulator: it amplifies deficient responses and dampens overactive ones, rather than simply boosting immunity.
- Toll-like receptor agonism: binds TLR2, 3, 4, 7, and 9 on dendritic cells (TLR9 is the signature action), activating MyD88, IRF3, and NF-κB signaling.
- Dendritic-cell maturation: primes a Th1-biased response, shifting adaptive immunity toward the cell-mediated arm that handles intracellular viruses and tumors.
- T-cell reconstitution: drives maturation of CD4+ helper and CD8+ cytotoxic T-cells and opposes cortisol-induced thymocyte apoptosis, the basis for its use in lymphopenic states.
- NK-cell activation and cytokine rebalancing: raises IL-2, IFN-γ, and IL-12 while suppressing excess IL-6, TNF-α, and IL-1β during cytokine storms.
- Zinc dependency: it needs zinc to fold into its active shape, so subclinical zinc deficiency blunts the response.
- Mechanisms include T-cell, dendritic-cell, NK-cell, Toll-like receptor, and antiviral immune modulation. It is immune-regulatory, not simply immune-boosting. The mechanism here is a plausibility map, not proof of a clinical outcome.
- Chronic hepatitis B: multiple RCTs and a 2001 meta-analysis (Chan et al.) showed improved HBeAg seroconversion at 1.6 mg twice weekly for 6 months, comparable-to-superior to interferon-α. This is its core approved indication.
- Chronic hepatitis C: pegylated-interferon plus Tα1 helped prior non-responders (Rustgi et al.), now largely replaced by direct-acting antivirals.
- Sepsis, ETASS to TESTS: the 2013 ETASS trial (361 patients) showed a 9% absolute mortality reduction (26.0% vs 35.0%), but the definitive 2025 TESTS trial (1,106 patients, BMJ) was negative (23.4% vs 24.1%). Benefit in unselected sepsis is now uncertain, though severely immunosuppressed subgroups may still gain.
- Cancer: as an adjuvant after curative resection of HBV-related hepatocellular carcinoma, a 2022 analysis (Linye et al.) found improved recurrence-free survival.
- COVID-19: a 2020 retrospective of 76 severe cases (Liu et al.) reported lower mortality and restored CD4+/CD8+ counts. Disease context and study design matter; These results do not generalize to broad immune support.
- Clinical literature exists in hepatitis, cancer-adjunct, sepsis, and immune contexts, but study quality and regional use vary. Do not generalize all immunology findings to wellness immunity. These are separate tiers of evidence: preclinical data, regional human reports, approved-product evidence, and community anecdotes.
Below you'll find reported clinical-label, research, and community-use dosing contexts where available. It's educational reference only, not dosing instructions for you.
- Protocol 1: Approved (Zadaxin / HBV) [Ex-US Approved/Label (Not FDA-approved in U.S.)]; Route: Subcutaneous; Dose: 1.6 mg; Frequency: Twice weekly; Duration: 6 to 12 months; Status: No - thymalfasin/Zadaxin protocol is not FDA-approved in the United States.
- Protocol 2: General Immune Support [Community/Biohacker/Anecdotal]; Route: Subcutaneous; Dose: 0.8 mg – 1.6 mg; Frequency: 1 to 2 times weekly; Duration: 4 to 8 weeks (cycled); Status: No - research, clinical trial, off-label, community/anecdotal, cosmetic, or otherwise not FDA-approved as written.
- Protocol 3: Acute Loading (Viral / Sepsis) [Clinical/Human Trial]; Route: Subcutaneous; Dose: 1.6 mg; Frequency: Daily; Duration: 5 to 7 days, then taper; Status: No - research, clinical trial, off-label, community/anecdotal, cosmetic, or otherwise not FDA-approved as written.
- Protocol 4: Community loading-to-maintenance pattern [Community/Biohacker/Anecdotal]; Route: Subcutaneous; Dose: 1.6 mg daily for first 5 to 7 days; Then 1.6 mg twice weekly; Duration: 4 to 8 weeks after step-down; Subsequent cycles 1.6 mg twice weekly for 4 weeks, 2 to 3 times per year; Status: No - research, clinical trial, off-label, community/anecdotal, cosmetic, or otherwise not FDA-approved as written.
- Ex-U.S. product dosing, trial dosing, and community dosing are separate. Immune context and indication matter more than generic cycle numbers. Protocol rows are educational context, not personalized instructions, and product-label directions control when an approved product exists.
- Time until steady state: roughly 8 to 10 hours by half-life math, but daily dosing does not necessarily produce clinically meaningful accumulation.
- Half-life basis: FDA compounding-review material cites a subcutaneous half-life around 2 hours and no accumulation after daily dosing for 5 days.
- Beginner translation: The immune effect is not simply the blood level. Immune-cell signaling may change after the peptide itself has cleared.
- Practical interpretation: Match any claim to the studied indication. Monitor clinical context and immune/inflammatory markers rather than assuming a generic steady-state benefit.
- Human PK has been characterized in product contexts, but immune effects are downstream. Half-life alone does not predict immune response. PK estimates are most useful for timing and accumulation awareness, not for proving efficacy or safety.
- Zinc (essential cofactor): Tα1 needs zinc to fold correctly, so checking RBC zinc and, if low, supplementing 15 to 30 mg zinc glycinate daily is standard in integrative protocols.
- Thymosin Beta-4 (TB-500): complementary, not redundant. Tα1 modulates T-cell and innate immunity while T-beta-4 drives tissue repair.
- Vitamin D, BPC-157, probiotics, glutathione, NAC: complementary immune or gut-recovery support with no known interactions.
- Interferon-α (clinical): historically stacked for chronic HBV and HCV; Augments antiviral response but adds interferon's flu-like effects.
- Oncology adjuncts: added to chemotherapy in HCC, NSCLC, and melanoma (Garaci et al.) to offset immunosuppression; Early 2025 interest pairs it with PD-1/PD-L1 checkpoint inhibitors to restore dendritic-cell function.
- Often paired with vaccines, antivirals, cancer adjuncts, or immune stacks in discussion. Combining immune modulators can obscure benefit and risk, especially in autoimmune disease. A sound stack accounts for both mechanism overlap and additive safety, tolerability, and interpretation risks.
One of the strongest safety records of any peptide here: across 3,000+ patients and 70+ studies, toxicity has been close to placebo.
- Common: mild injection-site redness, itching, or discomfort (low single-digit incidence).
- Uncommon: transient fatigue, mild flu-like symptoms, or headache in the first days; Transient mild ALT elevation in some HCV trials.
- No immune-overactivation pattern: unlike interferon-α or IL-2, it does not cause high fever, rigors, cytopenia, or CNS toxicity at standard doses.
- Absolute contraindication: deliberate immunosuppression (transplant recipients on tacrolimus or cyclosporine, high-dose corticosteroids), where immune stimulation could precipitate graft rejection.
- Use caution in active autoimmune flare (MS, SLE, RA), known hypersensitivity to the peptide or excipients (mannitol, sodium phosphate), pregnancy or breastfeeding, and severe liver failure (monitor ALT).
- Usually described as well tolerated in studied contexts, but autoimmune disease, transplant immunosuppression, cancer therapy, and pregnancy require caution. Product purity matters for injectable use. The honest safety picture covers both known risks and uncertainty risks, especially where human data are limited.
Because it is an immunomodulator, the useful markers are immune readouts, not organ-toxicity panels.
- Baseline: CBC with differential, CD4+ and CD8+ counts with the CD4/CD8 ratio, NK count and activity where available, serum or RBC zinc, ALT/AST, hs-CRP, and disease-specific markers (HBV DNA, HCV RNA, tumor markers, autoimmune panels).
- During therapy (every 4 to 8 weeks): CD4/CD8 counts and ratio (changes usually visible by 4 to 6 weeks), hs-CRP, ALT/AST, the relevant disease markers, plus infection frequency and recovery speed.
- Longer-term research markers: monocyte HLA-DR expression (the key restoration marker in the ETASS sepsis trial), sjTREC for fresh thymic output, and serum Tα1 by ELISA (baseline levels run low in chronic autoimmune disease).
- Track infection frequency/severity, CBC with differential when clinically relevant, inflammatory/autoimmune symptoms, liver markers in hepatitis contexts, and adverse reactions. Useful monitoring matches the claimed goal, the most plausible risk, and objective baseline measures.
- FDA (US): not approved. Placed in Category 2 (do-not-compound) in late 2023; The nominators withdrew in 2024, which removed it from Category 2 without a Category 1 determination, the same path as CJC-1295 and Ipamorelin.
- Under review: expected to be referred to a future Pharmacy Compounding Advisory Committee meeting. It was not among the 12 peptides in the April 15, 2026 HHS action, and interim compounding access is contested.
- Zadaxin (thymalfasin): approved in 35+ countries for chronic HBV, chronic HCV, and immune-adjuvant use, with FDA Orphan Drug Designation for HCC, chronic HBV, and DiGeorge syndrome.
- WADA: not prohibited. It is treated as an immunomodulator with no anabolic or growth-factor activity, unlike thymosin beta-4, which is banned under S2.
- FDA materials state Ta1 is not approved in the United States and no FDA-approved drug products contain Ta1. Ex-U.S. approval stands separately. Regulatory status spans distinct categories: FDA approval, ex-U.S. approval, investigational development, compounding review, supplement/cosmetic status, and RUO-market availability.